Puma Biotechnology (PBYI) Cash from Operations Growth (3y) (2013 - 2026)
Puma Biotechnology (PBYI) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Puma Biotechnology | 409.56 Mn | 371.27 Mn | 34.39 Mn | 80.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.01% |
| Dec 31, 2025 | 23.35% |
| Sep 30, 2025 | -17.51% |
| Jun 30, 2025 | 44.46% |
| Mar 31, 2025 | 28.75% |
| Dec 31, 2024 | 69.52% |
| Sep 30, 2024 | 1.69% |
| Jun 30, 2024 | 151.34% |
| Mar 31, 2024 | -10.45% |
| Dec 31, 2023 | 56.80% |
| Sep 30, 2023 | 83.43% |
| Jun 30, 2023 | -41.22% |
| Mar 31, 2023 | 30.63% |
| Dec 31, 2022 | 69.92% |
| Sep 30, 2022 | 63.39% |
| Jun 30, 2022 | -32.26% |
| Mar 31, 2022 | -18.58% |
| Dec 31, 2021 | -40.46% |
| Sep 30, 2021 | 51.04% |
| Jun 30, 2021 | 83.87% |